Skip to main content

Table 3 Multivariate analysis of renal outcome within 4-year

From: Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

 

eGFR < 60 mL/min/1.73 m2

eGFR reduction > 30% than baseline

eGFR < 60 mL/min/1.73 m2 or reduction > 30%

Odds Ratio (95%CI)

p

Odds Ratio (95%CI)

p

Odds Ratio (95%CI)

p

Male sex

0.9 (0.65–1.24)

0.512

0.53 (0.39–0.71)

< 0.001

0.59 (0.46–0.76)

< 0.001

Age (by 10 years)

1.91 (1.65–2.22)

< 0.001

1.38 (1.21–1.58)

< 0.001

1.46 (1.30–1.63)

< 0.001

Duration of diabetes (by 5 years)

0.95 (0.89–1.01)

0.107

1.01 (0.94–1.08)

0.819

0.98 (0.93–1.04)

0.500

BMI

 27–30 Kg/m2

0.93 (0.61–1.43)

0.754

1.02 (0.68–1.53)

0.924

1.09 (0.77–1.53)

0.636

 > 30 Kg/m2

1.16 (0.67–2.02)

0.599

0.92 (0.52–1.63)

0.770

1.15 (0.73–1.81)

0.543

Albuminuria

 Microalbuminuria

1.55 (1.00–2.40)

0.048

1.87 (1.27–2.76)

0.002

1.44 (1.01–2.06)

0.045

 Macroalbuminuria

4.30 (2.19–8.46)

< 0.001

5.12 (2.81–9.35)

< 0.001

4.09 (2.33–7.16)

< 0.001

 eGFR below 90 mL/min/1.73 m2 (by 5)

1.79 (1.64–1.96)

< 0.001

0.87 (0.78–0.97)

0.014

1.46 (1.36–1.57)

< 0.001

 HbA1c ≥ 7%

1.08 (0.73–1.60)

0.695

1.17 (0.82–1.66)

0.386

1.13 (0.83–1.53)

0.437

 Triglycerides ≥150 mg/dl

1.48 (0.88–2.50)

0.139

2.00 (1.28–3.12)

0.002

1.84 (1.24–2.74)

0.003

 HDL < 40 M <50F mg/dL

0.83 (0.50–1.39)

0.480

1.09 (0.71–1.68)

0.695

1.04 (0.71–1.52)

0.835

 LDL ≥100 mg/dL

1.08 (0.78–1.49)

0.651

0.83 (0.62–1.12)

0.229

0.93 (0.72–1.21)

0.596

 BP ≥ 140/85 mmHg

1.12 (0.81–1.55)

0.503

1.35 (0.98–1.85)

0.064

1.24 (0.95–1.61)

0.118

 Non-proliferative retinopathy

1.09 (0.75–1.58)

0.656

0.76 (0.52–1.10)

0.150

0.86 (0.63–1.17)

0.345

 Proliferative retinopathy

1.42 (0.87–2.31)

0.162

1.19 (0.74–1.93)

0.477

1.18 (0.78–1.78)

0.443

 Lipid-lowering treatment

0.87 (0.61–1.25)

0.464

0.85 (0.59–1.22)

0.370

0.87 (0.65–1.18)

0.373

 Antihypertensive treatment

1.31 (0.90–1.90)

0.155

1.23 (0.86–1.77)

0.256

1.21 (0.90–1.65)

0.211

 Aspirin

1.26 (0.83–1.91)

0.273

1.45 (0.95–2.23)

0.089

1.44 (1.01–2.05)

0.046

 Insulin pump

1.76 (0.91–3.39)

0.091

0.97 (0.54–1.74)

0.909

1.21 (0.73–1.99)

0.461

Separate models

 Serum uric acid (mg/dL)

1.07 (0.96–1.20)

0.211

1.04 (0.94–1.16)

0.460

1.04 (0.95–1.15)

0.393

 Serum uric acid in the top quintile

1.44 (0.90–2.31)

0.130

1.20 (0.75–1.89)

0.447

1.29 (0.88–1.90)

0.197

 Smokers

0.67 (0.37–1.22)

0.190

1.14 (0.71–1.83)

0.599

0.84 (0.54–1.29)

0.423

  1. Multivariate models were fitted including a missing indicator variable to indicate whether the BMI value is missing. Serum uric acid and smoking status evaluated in separate models that included patients with complete data
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us